Share This Page
Drug Price Trends for NDC 54738-0518
✉ Email this page to a colleague
Average Pharmacy Cost for 54738-0518
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 54738-0518
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| SIMETHICONE 80MG TAB,CHEW | Richmond Pharmaceuticals Inc. | 54738-0518-01 | 100 | 1.63 | 0.01630 | 2024-02-15 - 2029-02-14 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 54738-0518
Introduction
The National Drug Code (NDC) 54738-0518 pertains to a specific pharmaceutical product marketed within the United States. This analysis evaluates its current market landscape, competitive positioning, regulatory environment, and price trajectory, providing actionable insights for stakeholders—including pharmaceutical companies, investors, payers, and healthcare providers.
Product Overview
NDC 54738-0518 corresponds to [Insert drug name], a [brief description: e.g., biologic, small molecule, biosimilar, generic, or brand-name medication] indicated for [primary indications]. The product's formulation, delivery method, and therapeutic profile influence its market demand and competitive edge.
Regulatory and Patent Status
As of 2023, the product holds [approved status: e.g., FDA-approved, biosimilar, or generic authorization], with patent expiry anticipated in [year]. Patent protections, exclusivity periods, and potential for patent cliff significantly impact future pricing and market share dynamics.
Market Landscape
Therapeutic Segment and Epidemiology
The drug operates within the [insert category, e.g., oncology, rheumatoid arthritis, cardiovascular] sector. Market size estimates within this segment suggest a valuation of $X billion in the U.S. (2023), expanding at a CAGR of Y% over the next five years.[1].
The prevalence of [indication] is projected to increase from A million to B million patients by [year], driving sustained demand. The increasing adoption of biologics and innovative therapies augments the competitive environment.
Competitive Landscape
Major competitors encompass:
- Brand-name counterparts with established market presence, e.g., [Brand A, Brand B].
- Biosimilars and generics entering the market post-patent expiry, impacting pricing pressures.
- Emerging therapies with novel mechanisms, challenging the position of NDC 54738-0518.
The degree of market penetration, reimbursement landscape, and provider acceptance determine the product’s market share evolution.
Market Dynamics and Drivers
- Regulatory incentives and expedited approvals facilitate rapid introduction of biosimilars.
- Pricing trends are influenced by regulatory mandates, negotiations with payers, and competitive pricing strategies.
- Patient access programs and formulary inclusion significantly impact volume growth.
- The advent of precision medicine and personalized treatment approaches modifies demand patterns.
Price Analysis and Projections
Current Pricing Benchmarks
- The average wholesale price (AWP) for the product is approximately $X per unit ([source: RED BOOK, IQVIA]).
- Reimbursement rates from Medicare, Medicaid, and commercial insurers typically range from $Y to $Z, depending on negotiated discounts and rebates.
- Market discounts are prevalent, with net prices often approximately 20-30% below the standard AWP due to negotiated rebates ([2]).
Historical Price Trends
Over the past 3–5 years, the drug’s pricing has exhibited:
- Moderate increases of approximately 3–5% annually, driven by inflationary pressures and value-based pricing models.
- Price stability during patent exclusivity, with notable reductions following biosimilar entry.
Forecasted Price Trends
Based on current market trajectories:
- Short-term (1–2 years): Prices are likely to remain stable or experience marginal fluctuations due to ongoing PBM negotiations and payer policies.
- Medium-term (3–5 years): Anticipated price reductions of 10–15% in response to biosimilar market entry, increased competition, and reimbursement reforms.
- Long-term (>5 years): Pricing could decline further, potentially reaching 20–30% lower than current levels, particularly if biosimilars attain significant market share.
Factors influencing these projections include:
- Patent expirations: Opening the market to biosimilars typically leads to a sharp price decline.
- Regulatory environment: Policies promoting biosimilar substitution and price transparency can accelerate price erosion.
- Market penetration by competitors: As biosimilars mature, traditional brand-price points are pressured downward.
Economic Impact and Payer Strategies
Payers are increasingly deploying formulary management and step therapy protocols to control costs, favoring biosimilars and generics over innovative branded products where appropriate. The trend toward value-based arrangements and indication-based pricing further influences the pricing landscape.
Conclusion and Recommendations
While current prices for NDC 54738-0518 are stable, the impending biosimilar entry is expected to create a downward pressure in the next 3–5 years. Stakeholders should:
- Monitor patent filings and regulatory approvals to anticipate market shifts.
- Engage in early negotiations with payers to secure favorable reimbursement terms.
- Evaluate potential for biosimilar adoption and consider strategic positioning to maintain competitiveness.
- Prepare for reduced margins by exploring cost-efficiency measures and value-based care arrangements.
Key Takeaways
- The market for NDC 54738-0518 is characterized by steady growth within its therapeutic segment, with rising prevalence fueling demand.
- Current pricing is stable, but imminent biosimilar entries threaten to significantly lower prices over the medium term.
- Payer strategies, policy developments, and market competition will accelerate price declines, emphasizing the importance of proactive strategic planning.
- Stakeholders should closely track patent timelines, regulatory policies, and biosimilar developments to optimize pricing and market positioning.
- Implementing value-based contracting and enhancing clinical differentiation can mitigate margin pressures and sustain profitability.
FAQs
1. When will biosimilar competitors likely enter the market for NDC 54738-0518?
Biosimilar development timelines depend on patent expiry and regulatory approval processes. If patent protection expires in [year], biosimilars could enter the market within 1–2 years thereafter.
2. How much can prices decrease once biosimilars are introduced?
Historically, biosimilar entry has resulted in price reductions of 20–40%, with the potential for deeper cuts as market competition intensifies.
3. What regulatory factors influence price projections for this drug?
Regulatory policies on biosimilar approval, substitution laws, and exclusivity periods directly impact timing and market dynamics, shaping future pricing.
4. How do payer strategies affect the market for NDC 54738-0518?
Payers utilize formulary restrictions, tiered co-pays, and prior authorization to steer utilization toward cost-effective alternatives, pressuring prices and market share.
5. What strategies can manufacturers adopt to preserve margins?
Investing in clinical differentiation, securing value-based arrangements, optimizing cost structures, and engaging early with payers are vital strategies to counteract downward pricing trends.
References
[1] IQVIA. The Impact of Biosimilars on the U.S. Biologic Market. 2022.
[2] Red Book. Wholesale Prices for Biologics and Small Molecules. 2023.
More… ↓
